Why the study?
Does micronized fenofibrate improve lipid profiles compared to simvastatin in patients with primary type IIa or IIb hyperlipoproteinemia?
Population
133 men and women with primary type IIa or IIb hyperlipoproteinemia following 8 weeks of dietary treatment.
Comparison
Micronized fenofibrate 200 mg/day for 12 weeks vs Simvastatin 20 mg/day for 12 weeks
Design
RCT, randomized
Follow-up
12 weeks
Authors
Loading...
Prioritizes simvastatin for LDL and fenofibrate for triglycerides in type IIb; extends RCT evidence for lipid-specific therapy selection.
Does micronized fenofibrate improve lipid profiles compared to simvastatin in patients with primary type IIa or IIb hyperlipoproteinemia?
Simvastatin is superior for LDL reduction, while fenofibrate provides greater benefits for triglycerides, HDL, fibrinogen, and uric acid, particularly in type IIb hyperlipidemia.
Steinmetz et al. (1996) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: